In late 2002, a life-threatening febrile respiratory illness appeared in Guangdong Province, China, and quickly spread throughout Asia and to other parts of the world ([@R1]--[@R4]). Designated "severe acute respiratory syndrome" (SARS), the etiologic agent was later identified as a hitherto unrecognized coronavirus (SARS-CoV) ([@R5],[@R6]). A diagnosis of SARS is based primarily on clinical and epidemiologic criteria, but many respiratory viruses can cause similar symptoms, and therefore rapid, reliable diagnostic tests for SARS-CoV infection were needed. In response to this need, three types of diagnostic tests for SARS-CoV were quickly developed: tissue culture isolation, antibody detection, and reverse transcription-polymerase chain reaction (RT-PCR) assays.

A variety of RT-PCR assays were developed during the epidemic for SARS-CoV ([@R1],[@R5]--[@R8]), including a commercial ready-to-use RT-PCR kit (Artus Biotech, Hamberg, Germany). Early assays based on conventional designs that required postamplification product processing (e.g., gel electrophoresis), were time-consuming and prone to false-positive results from amplicon contamination. Conversely, real-time RT-PCR assays based on detecting and quantifying a fluorescent signal generated during amplification do not require postamplification processing and therefore eliminate one potential avenue for template contamination.

A variant of the real-time format, based on TaqMan probe hydrolysis technology (Applied Biosystems, Foster City, CA), has been shown to provide sensitive, specific, and quantifiable results in viral diagnostic assays ([@R9]) and has been used successfully to study emerging virus infections ([@R10],[@R11]), including SARS ([@R6],[@R12]). In response to the SARS public health emergency, we developed and evaluated a TaqMan real-time RT-PCR assay based on three distinct targets in the SARS-CoV genome for rapid deployment to the National Laboratory Response Network for Bioterrorism (LRN) (<http://www.cdc.gov/programs/bio.htm>).

Materials and Methods
=====================

Clinical Specimens
------------------

A total of 177 clinical specimens collected from 66 patients who met the SARS case definition ([@R13]) were used in this study. Specimens included oro- and nasopharyngeal swabs (dry and in viral transport media), sputa, nasal aspirates and washes, bronchoalveolar lavage, and lung tissue specimens collected at autopsy. Specimen processing was performed in a class II biological safety cabinet using biosafety level three (BSL3) work practices. Three 100-μL aliquots of each specimen were distributed to vials each containing 900 μL of NucliSens lysis buffer (bioMérieux, Durham, NC) and stored at --70°C until testing.

Virus Culture
-------------

Vero E6 cells were inoculated with clinical specimens and observed for cytopathic effect, consisting of cell rounding with a refractive appearance followed by detachment from the flask surface ([@R5]). Plaque titrations were conducted by standard methods ([@R14]).

Nucleic Acid Extraction
-----------------------

Nucleic acids were recovered from clinical specimens using the automated NucliSens extraction system (bioMérieux). Following manufacturer's instructions, specimens received in NucliSens lysis buffer were incubated at 37°C for 30 min with intermittent mixing, and 50 μL of silica suspension, provided in the extraction kit, was added and mixed. The contents of the tube were then transferred to a nucleic acid extraction cartridge and processed on an extractor workstation. Approximately 40--50 μL of total nucleic acid eluate was recovered into nuclease-free vials and either tested immediately or stored at --70°C.

Primers and Probes
------------------

Multiple primer and probe sets were designed from the Urbani strain of SARS-CoV polymerase 1b and nucleocapsid gene sequences ([@R15]) by using Primer Express software version 1.5 or 2.0.0 (Applied Biosystems) with the following default settings: primer melting temperature (T~M~) set at 60°C; probe T~M~ set at 10°C greater than the primers at approximately 70°C; and no guanidine residues permitted at the 5′ probe termini. All primers and probes were synthesized by standard phosphoramidite chemistry techniques at the Biotechnology Core Facility at the Centers for Disease Control and Prevention (CDC). TaqMan probes were labeled at the 5′-end with the reporter molecule 6-carboxy-fluorescein and at the 3′-end with the quencher Blackhole Quencher 1 (Biosearch Technologies, Inc., Novato, CA). Optimal primer and probe concentrations were determined by crosstitration of serial twofold dilutions of each primer against a constant amount of purified SARS-CoV RNA. Primer and probe concentrations that gave the highest amplification efficiencies in this study were selected for further study ([Table 1](#T1){ref-type="table"}).

###### Primers and probes used for real-time RT-PCR assays^a^

  Assay ID                      Primer/ probe   Sequence (5′\>3′)                       Genomic region            Location^b^
  ----------------------------- --------------- --------------------------------------- ------------------------- -------------
  Primary diagnostic assay                                                                                        
  SARS1                         F               CAT GTG TGG CGG CTC ACT ATA T           RNA polymerase            15370-15392
                                R               GAC ACT ATT AGC ATA AGC AGT TGT AGC A                             15422-15449
                                P               TTA AAC CAG GTG GAA CAT CAT CCG GTG                               15395-15420
  SARS2                         F               GGA GCC TTG AAT ACA CCC AAA G           Nucleocapsid              28531-28552
                                R               GCA CGG TGG CAG CAT TG                                            28581-28597
                                P               CCA CAT TGG CAC CCG CAA TCC                                       28559-28574
  SARS3                         F               CAA ACA TTG GCC GCA AAT T               Nucleocapsid              29016-29034
                                R               CAA TGC GTG ACA TTC CAA AGA                                       29063-29083
                                P               CAC AAT TTG CTC CAA GTG CCT CTG CA                                29036-29061
  To confirm positive results                                                                                     
  N3                            F               GAA GTA CCA TCT GGG GCT GAG             Nucleocapsid              28432-28452
                                R               CCG AAG AGC TAC CCG ACG                                           28383-28400
                                P               CTC TTT CAT TTT GCC GTC ACC ACC AC                                28406-28431
  3′NTR                         F               AGC TCT CCC TAG CAT TAT TCA CTG         3′ nontranslated region   29619-29642
                                R               CAC CAC ATT TTC ATC GAG GC                                        29576-29595
                                P               TAC CCT CGA TCG TAC TCC GCG T                                     29597-29618
  M                             F               TGT AGG CAC TGA TTC AGG TTT TG          Membrane protein          26951-26973
                                R               CGG CGT GGT CTG TAT TTA ATT TA                                    27005-27027
                                P               CTG CAT ACA ACC GCT ACC GTA TTG GAA                               26974-27000

^a^RT-PCR, reverse transcription--polymerase chain reaction; F, forward primer; R, reverse primer; P, probe. ^b^Location based on the severe acute respiratory syndrome--associated coronavirus, Urbani strain (GenBank accession number AY278741).

Real-Time RT-PCR Assay
----------------------

The real-time RT-PCR assay was performed by using the Real-Time One-Step RT-PCR Master Mix (Applied Biosystems). Each 25-μL reaction mixture contained 12.5 μL of 2X Master Mix, 0.625 μL of the 40X MultiScribe and RNase Inhibitor mix, 0.25 μL of 10 μM probe, 0.25 μL each of 50 μM forward and reverse primers, 6.125 μL of nuclease-free water, and 5 μL of nucleic acid extract. Amplification was carried out in 96-well plates on an iCycler iQ Real-Time Detection System (Bio-Rad, Hercules, CA). Thermocycling conditions consisted of 30 min at 48°C for reverse transcription, 10 min at 95°C for activation of the AmpliTaq Gold DNA polymerase, and 45 cycles of 15 s at 95°C and 1 min at 60°C. Each run included one SARS-CoV genomic template control and at least two no-template controls for the extraction (to check for contamination during sample processing) and one no-template control for the PCR-amplification step. As a control for PCR inhibitors, and to monitor nucleic acid extraction efficiency, each sample was tested by real-time RT-PCR for the presence of the human ribonuclease (RNase) P gene (GenBank accesssion number NM_006413) by using the following primers and probe: forward primer 5′-AGATTTGGACCTGCGAGCG-3′; reverse primer 5′-GAGCGGCTGTCTCCACAAGT-3′; probe 5′-TTCTGACCTGAAG GCTCTGCGCG-3′. The assay reaction was performed identically to that described above except that primer concentrations used were 30 μM each. Fluorescence measurements were taken and the threshold cycle (C~T~) value for each sample was calculated by determining the point at which fluorescence exceeded a threshold limit set at the mean plus 10 standard deviations above the baseline. Clinical samples were considered positive if two or more of the SARS genomic targets showed positive results (C~T~ ≤45 cycles) and all positive and negative control reactions gave expected values.

Clinical specimens submitted to CDC for SARS-CoV testing that gave positive results were confirmed with a TaqMan real-time RT-PCR assay based on three different primer and probe sets ([Table 1](#T1){ref-type="table"}). This assay was performed independently in a separate laboratory using newly extracted nucleic acid from a second specimen aliquot. The confirmatory assay used the SuperScript One-Step RT-PCR (Invitrogen Corp., Carlsbad, CA) and the Mx4000 Multiplex Quantitative PCR system (Stratagene, La Jolla, CA).

Synthesis of RNA Transcripts
----------------------------

Template for the nucleocapsid gene RNA was plasmid DNA (pCRII, Invitrogen Corp.) containing a full-length copy of the open reading frame for the SARS-CoV nucleocapsid gene oriented behind a T7 promoter. The plasmid was linearized by digestion with *Spe*I. The template for the polymerase RNA was a RT-PCR product generated by using the following primers: Cor-p-F2-T7, 5′-GTA ATA CGA CTC ACT ATA GGG CTA ACA TGC TTA GGA TAA TGG-3′ and Cor-p-R2, 5′-CCT ATT TCT ATA GAG ACA CTC-3′. Approximately 1 μg of RNA from Vero cells infected with SARS-CoV was used in RT-PCR reactions performed by using the SuperScript RT-PCR kit (Invitrogen Corp.) according to the manufacturer's instructions; both templates were purified by phenol-chloroform extraction and ethanol precipitation before being used for in vitro transcription. RNA was synthesized in vitro by using the MegaScript kit (Ambion Inc., Austin, TX) according to the standard protocol. Synthetic RNA was treated with RNase-free DNase before being purified by phenol-chloroform extraction and ethanol precipitation. The concentration of RNA was determined by use of UV spectroscopy. Synthetic RNA was positive sense and 1,369 nt in length for N and 325 nt in length for polymerase.

Results
=======

Real-Time RT-PCR Sensitivity and Reproducibility
------------------------------------------------

Tenfold serial dilutions of the polymerase and nucleocapsid RNA transcripts were tested to assess the copy detection limits and dynamic range of our optimized real-time RT-PCR assays. The lower potential limit of detection was approximately 2 transcript copies per reaction for SARS2 and SARS3, and 7.5 copies per reaction for SARS1 ([Figure](#F1){ref-type="fig"}). The confirmatory assays, which employ three different primer and probe sets (N3, 3′NTR, and M), showed potential limits of detection similar to the SARS2 and SARS3 assays. Strong linear correlations (r^2^ ≥0.99) were obtained between C~T~ values and transcript quantity over at least a 6-log range from approximately 10^2^ to 10^7^ copies per reaction for the three primer/probe sets. Linearity was markedly reduced for copy numbers exceeding 10^6^ (data not shown).

![Typical amplification plot derived from serial 10-fold dilutions of severe acute respiratory syndrome--associated coronavirus RNA transcripts using TaqMan reverse transcription--polymerase chain reaction primer/probe sets SARS1, SARS2, and SARS3. A PCR Base Line Subtractive Curve Fit view of the data is shown with relative fluorescence units (RFU) plotted against cycle number. The default setting of 10 times the standard deviation of fluorescence in all wells over the baseline cycles was used to calculate the threshold cycle, or C~T~ value, for a positive reaction (horizontal line). Inserts show standard curve analysis of the RNA amplification plots with C~T~ values plotted against starting copy number. Plots derived from dilutions containing 2 x 10^6^ to 20 transcript copies for SARS2 and SARS3, and 7.5 x 10^6^ to 75 copies for SARS1.](03-0759-F){#F1}

Assay reproducibility was tested by using replicate 10-fold serial dilutions of the RNA transcripts and intra- and interassay variability evaluated for each dilution point in triplicate on three different days. At the lower copy detection limit for SARS2 and SARS3 (2 copies per reaction), assay reproducibility exceeded 90%. In contrast, the lower copy detection limit for SARS1 (7.5 copies per reaction) was positive in \<50% of replicate reactions. One hundred percent reproducibility with SARS1 was achieved at the dilution that contained 75 transcript copies per reaction. Over the linear range of the assay, the coefficient of variation of the mean C~T~ values within and between runs was 0.46%--2.54% and 0.64%--2.39%, respectively ([Table 2](#T2){ref-type="table"}).

###### Reproducibility of real-time RT-PCR assays^a^

                             RNA transcript copy number^b^                                                           
  -------------------------- ------------------------------- ------------- ------------- ------------- ------------- -------------
  SARS1                      7.5 x 10^1^                     7.5 x 10^2^   7.5 x 10^3^   7.5 x 10^4^   7.5 x 10^5^   7.5 x 10^6^
  CV within assay (%)^c^     2.53                            0.96          0.49          0.69          1.66          0.7
  CV between assays (%)^d^   2.39                            1.09          0.82          0.64          2.1           0.79
  SARS2                      2.0 x 10^1^                     2 x 10^2^     2 x 10^3^     2 x 10^4^     2 x 10^5^     2 x 10^6^
  CV within assay (%)        1.27                            0.57          0.46          0.72          0.84          0.67
  CV between assays (%)      1.54                            1.18          0.93          1.47          1.54          1.32
  SARS3                                                                                                              
  CV within assay (%)        0.8                             0.55          0.65          0.5           0.27          1.25
  CV between assays (%)      0.94                            0.64          1.07          1.13          1.24          1.65

^a^RT-PCR, reverse transcription--polymerase chain reaction; CV, coefficient of variation. ^b^Ten-fold dilutions of the polymerase and nucleocapsid RNA transcripts; copies per reaction; dilution series thawed on 3 different days and assays performed in triplicate for each dilution. ^c^Determined from three replicates within each assay. ^d^Determined from three independent assays performed on different days.

To assess the efficiency of amplification of the RNA transcripts in the presence of exogenous nucleic acid and potential RT-PCR inhibitors, 10-fold serial dilutions of the RNA transcripts were prepared in water and pooled total nucleic acid extract from 20 SARS-CoV--negative human respiratory specimens (nasopharyngeal aspirates, bronchial washes, sputum, naso- and oropharyngeal swabs, and lung tissue). Exogenous nucleic acid had no discernible effect on amplification efficiency of the SARS1 and SARS3 primer/probe sets, as demonstrated by the similarity in linear regression slopes and endpoint detection limits in the presence and absence of specimen extract ([Table 3](#T3){ref-type="table"}). In contrast, the standard curve for SARS2 had a more efficient slope (--3.21) in water than in the presence of spiked extract (--3.48) and with greater variation in the C~T~ values at 20 target copies or lower, suggesting that the amplification reaction was less efficient in the presence of the specimen extract. This observation was confirmed on two additional repetitions of the same experiment.

###### Efficiency of real-time PCR assays^a^

                                Mean C~T~^b^ values at estimated RNA transcript copy number                                                                                                  
  ----------------------------- ------------------------------------------------------------- ------------- ------------- ------------- ------------- ------------- ------------- ---------- -------------------
  SARS1                         7.5 x 10^0^                                                   7.5 x 10^1^   7.5 x 10^2^   7.5 x 10^3^   7.5 x 10^4^   7.5 x 10^5^   7.5 x 10^6^   Slope^c^   Efficiency (%)^d^
  RNA transcript alone          Neg                                                           38.65±1.48    34.25±0.57    31.1±0.14     27.5          24.2          20.55±0.07    --3.55     91.1
  RNA transcript + extract^e^   Neg                                                           38.05±0.92    34.85±0.21    31.55±0.07    27.75±0.07    24.4          20.6          --3.49     93.3
  SARS2                         2 x 10^0^                                                     2 x 10^1^     2 x 10^2^     2 x 10^3^     2 x 10^4^     2 x 10^5^     2 x 10^6^                
  RNA transcript alone          35.4±0.57                                                     32.1±0.14     29.45±0.64    26.15±0.07    22.9±0.14     19.4          16.35±0.07    --3.21     104.9
  RNA transcript + extract      Neg                                                           34.55±1.91    29.2±0.28     26.2          23.1          19.6±0.14     16.6          --3.48     93.9
  SARS3                                                                                                                                                                                      
  RNA transcript alone          39.3                                                          36.2±0.42     32.8          29.1±0.14     25.9          22.15±0.07    19.2          --3.39     97.1
  RNA transcript + extract      40.3                                                          36.2±0.28     33.4±0.28     29.9±0.21     26.05±0.07    22.55±0.21    19.65±0.21    --3.42     96.1

^a^PCR, polymerase chain reaction; CT, threshold cycle number. ^b^Values shown are mean of triplicate samples ± standard deviations. ^c^Slope determined from the formula: Y = Y intercept -- slope log~10.~ Slopes calculated for SARS1 (7.5 x 10^6^ to 7.5 x 10^1^); SARS2 (2 x 10^6^ to 2 x 10^1^); SARS3 (2 x 10^6^ to 2 x 10^0^). ^d^Efficiency = \[10^(--1/slope)^\] -- 1. ^e^Reactions performed in presence of pooled total nucleic acid extract from 20 human respiratory specimens.

The real-time RT-PCR assay was compared with a previously described conventional RT-PCR for SARS-CoV by using fluorescent dye-labeled primers and GeneScan amplicon analysis ([@R5]). Tenfold serial dilutions of a pretitrated SARS-CoV stock adjusted to 1 x 10^7^ PFUs/mL were prepared in triplicate and tested by all assays ([Table 4](#T4){ref-type="table"}). The real-time RT-PCR assays were positive with 100% frequency at a 10^--8^ dilution. Accordingly, the lowest virus quantity detected was 0.01 PFU/100 μL of specimen extract. The conventional RT-PCR assay was at least 10-fold less sensitive in repeat comparisons.

###### Comparison of real-time RT-PCR assays with culture and conventional RT-PCR^a^

  SARS-CoV dilution^b^   Conventional RT-PCR   Real-time RT-PCR         
  ---------------------- --------------------- ------------------ ----- -----
  10^--4^                3/3^c^                3/3                3/3   3/3
  10^--5^                3/3                   3/3                3/3   3/3
  10^--6^                3/3                   3/3                3/3   3/3
  10^--7^                3/3                   3/3                3/3   3/3
  10^--8^                0/3                   3/3                3/3   3/3
  10^--9^                0/3                   0/3                1/3   0/3
  10^--10^               0/3                   0/3                0/3   0/3

^a^RT-PCR, reverse transcription--polymerase chain reaction; SARS-CoV, severe acute respiratory syndrome--associated coronavirus. ^b^Serial 10-fold dilution of SARS-CoV stock culture containing 1 x 10^7^ PFUs/mL. ^c^Number of positive results divided by the number of replicates tested.

Specificity
-----------

We compared our primer and probe sets with sequences for 14 SARS-CoV field isolates that became available during the course of this study ([@R16]) and found no nucleotide mismatches. In contrast, alignments with other published human and animal coronaviruses (GenBank accession no.: human coronaviruses X69721 and AF124989; bovine coronaviruses NC003045 and AF124985; murine hepatitis viruses NC001846 and M55148; sialodacryoadenitis virus AF124990; canine coronavirus AF124986; feline infectious peritonitis virus AF124987; porcine hemagglutinating encephalomyelitis virus AF124988, Z34093, and AF124992; turkey coronavirus AF124991; and avian infectious bronchitis virus NC_001451) showed little sequence identity with our primer and probe sets. To further assess the potential for crossreactions with other members of the *Coronaviridae* family, the RT-PCR assays were tested against nucleic acid extracts of human respiratory coronaviruses OC43 (VR-759) and 229E (VR-740), feline infectious peritonitis virus (VR-3004), mouse hepatitis virus (VR-1426), bovine coronavirus (VR-874), porcine transmissible gastroenteritis virus (VR-743), and avian infectious bronchitis virus (VR-841), obtained from the American Type Culture Collection (Manassas, VA), and human enteric coronavirus (VR-1475). In addition, nucleic acid extracts of field isolates of influenza A and B; parainfluenza 1, 2, and 3; rhinovirus; adenovirus; human metapnuemovirus; and respiratory syncytial virus, as well as human and nonhuman primate cell lines were tested. No positive reactions were obtained with any of the primer and probe sets.

Evaluation with Clinical Specimens
----------------------------------

The real-time RT-PCR assay was used to test 14 clinical specimens (including throat swab \[2 specimens\], sputum \[1 specimen\], throat wash \[5 specimens\], and lung autopsy tissues \[6 specimens\]) from 10 patients with laboratory confirmed SARS-CoV infection ([Table 5](#T5){ref-type="table"}). Assay results were positive with all specimens for all three primer/probe sets. In addition, 326 respiratory specimens collected during the course of the outbreak from 236 suspected U.S. SARS patients who were serologically negative for SARS-CoV infection were also negative by the real-time RT-PCR.

###### Results of real-time RT-PCR assay with specimens from patients with laboratory-confirmed SARS-CoV infection^a^

  Case ID   Location    Specimen ID   Specimen      Serology   Vero E6 culture   Conventional RT-PCR^b^   Real-time RT-PCR C~T~^c^ values                 
  --------- ----------- ------------- ------------- ---------- ----------------- ------------------------ --------------------------------- ------ ------ ------
  05078     Toronto     2003756523    Lung, RM      N/A        --                \+                       24.2                              21.6   23     23.9
                        2003756525    Lung, RU                 --                \+                       24.9                              21.5   23     23.7
  05077     Thailand    2003756502    Throat swab   \+         \+                \+                       37.5                              36.2   39.8   29.3
  05000     Hong Kong   2003757035    Lung, RU      \+         --                \+                       26.7                              22.6   24.1   24.7
                        2003757036    Lung, LU                 --                \+                       27.2                              24.9   26.5   26
                        2003757037    Lung, RM                 --                \+                       34.9                              37.5   31.9   27.4
                        2003757038    Lung, LL                 --                \+                       29.6                              27     28.6   24.5
  00220     Utah, USA   2003757508    Sputum        \+         \+                \+                       24.7                              23     24.8   30.6
  05001     Vietnam     2003757190    Throat wash   \+         \+                \+                       23.7                              22.4   24.1   30.1
  05008     Vietnam     2003757229    Throat wash   \+         --                \+                       35.5                              35.5   36.7   30
  05010     Vietnam     2003757239    Throat wash   \+         --                \+                       31.1                              29.3   31.5   34.2
  05013     Vietnam     2003757251    Throat wash   \+         --                \+                       29.5                              28.4   30.3   28.8
  05017     Vietnam     2003757268    Throat wash   \+         \+                \+                       26                                24.7   26.4   27.9
  05316     Vietnam     2003759760    Throat swab   N/A        \+                N/A                      25                                25.3   28.2   28

^a^RT-PCR, reverse transcription--polymerase chain reaction; SARS-CoV, severe acute respiratory syndrome--associated coronavirus; CT, threshold cycle number; RM, right middle; RU, right upper; LU, left upper; LL, left lower; N/A, not applicable. ^b^Ref. [@R5]. ^c^Values shown mean of duplicate values.

Discussion
==========

In response to the SARS outbreak, we developed a real-time RT-PCR assay based on multiple primer and probe sets designed to different genomic targets to facilitate sensitive and specific detection of SARS-CoV in clinical specimens. A potential detection limit of \<10 transcript copies was achieved with greater relative sensitivity than cell culture isolation or conventional RT-PCR. The potential for quantitation over a wide dynamic range (at least 6 logs) was demonstrated with low intra- and interassay variability and limited inhibition from exogenous nucleic acid extract from respiratory secretions. The increased sensitivity of the real-time RT-PCR assay over cell culture and conventional RT-PCR methods may aid detection of the virus at earlier stages of infection, when the virus is present at low titer in respiratory secretions ([@R8]). In addition, by eliminating the need for postamplification product processing, the real-time RT-PCR format permitted shortened turnaround time for reporting results, which proved critical during the SARS outbreak.

Although real-time RT-PCR offers clear advantages over more conventional RT-PCR formats, assay results must still be interpreted with caution. For example, the effectiveness of RT-PCR for detection of SARS-CoV in clinical specimens has been shown to be greatly influenced by the quantity, type, and timing of specimen collection ([@R8],[@R17]). False-negative results due to poor quality nucleic acid or presence of RT-PCR inhibitors can also be a concern. We addressed this by simultaneously testing for the human RNase P gene, which should be present in all adequately collected samples. False-negative results could also potentially arise from mutations occurring in the primer and probe target regions in the SARS-CoV genome. We addressed this by including multiple genetic targets in our assay and by carefully comparing our primer and probe sequences against published sequences of SARS-CoV as they became available. To avoid false-positive results, meticulous care was taken to prevent introduction of contaminating viral RNA or previously amplified DNA during preparation of the nucleic acid extracts and amplification reactions. In addition, all RT-PCR--positive specimens were retested from a second, unopened sample aliquot and confirmed in a second laboratory by using a real-time assay based on different genetic targets.

In conclusion, our real-time RT-PCR assay permitted rapid, sensitive, and specific detection of SARS-CoV in clinical specimens and provided needed diagnostic support during the recent SARS outbreak. Widely deploying this assay through the LRN will enhance our ability to provide a rapid response in the event of the possible return of SARS.
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